A new oral treatment for pancreatic cancer priced at $480,000 per year has drawn renewed attention to the rising financial costs associated with specialized oncology drugs.
Escalating Costs in Oncology Care
The annual price tag of $480,000 for the pancreatic cancer medication reflects what healthcare analysts and industry publications describe as a new normal for drug pricing in specialty cancer care.
As oral cancer therapies enter the market, the substantial costs associated with these treatments continue to spark discussion regarding the broader financial landscape of prescription medications and patient accessibility.
